Additional file 22 of Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma

Additional file 22: Table S9. Pathway enrichment of CEScore in pan-cancer

Additional file 25 of Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma

Additional file 25: Table S12. CRP genes and each coefficient

Additional file 8 of Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma

Additional file 8: Fig. S8. Construction and evaluation of nomograms for PFS. (A-B) The univariate (A) and multivariate (B) Cox analyses of clinicopathologic data and CRP score for PFS outcomes. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns: no significance. (C) The predictive nomogram of PFS at 1-, 3-, and 5-years in TCGA-KIRC. (D) Calibration plots of 1-, 3-, and 5-years were utilized to evaluate the predictive accuracy of PFS in the CRP model. (E–G) Decision curve analysis to assess the clinical utility of 1- (E), 3- (F), and 5-years (G) nomogram

Additional file 2 of Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma

Additional file 2: Fig. S2. CRGs expression analysis. (A) The paired tumor and normal samples were used to identify differential expression of CRGs in pan-cancer (14/32). (B) The subtype relevant changes of CRGs expression in pan-cancer; FDR: False discovery rate; FDR count: the significance of FDR

Additional file 13 of Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma

Additional file 13: Fig. S13. The relation between the mTORC1 signaling term and prognosis in pan-cancer cohort

Additional file 27 of Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma

Additional file 27: Table S14. Clinical baseline data of training cohort and validate cohorts in ccRCC

Additional file 19 of Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma

Additional file 19: Table S6. CEScore in pan-cancer

Additional file 24 of Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma

Additional file 24: Table S11. Univariate Cox analysis of cuproptosis-related targeted genes in KIRC

Additional file 7 of Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma

Additional file 7: Fig. S7. Sub-group Survival analysis of KIRC. (A-P) The survival curve plot shows differences in OS/PFS outcomes between high- and low-CRP scores in different clinical subgroups, including Stage (I-II: A and C, III-IV: B and D), Grade (I-II: E and G, III-IV: F and H), age ( 65: j and L), and Gender (Male: m and o, Female: N and P)

Additional file 20 of Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma

Additional file 20: Table S7. Cox analysis of CEScore in pan-cancer